EUS-Guided Rendezvous or Direct Interventions Versus Advanced ERCP Techniques for Biliary Access and Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01678326 |
Recruitment Status :
Completed
First Posted : September 5, 2012
Last Update Posted : February 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Disorders of Gallbladder Disorders of Biliary Tract | Procedure: EUS-Rendezvous or direct intervention Procedure: Advanced ERCP Biliary Access Techniques | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 226 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Endoscopic Ultrasound Guided Rendezvous or Direct Interventions Versus Advanced ERCP Techniques for Biliary Access and Therapy |
Study Start Date : | August 2012 |
Actual Primary Completion Date : | December 2019 |
Actual Study Completion Date : | December 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: EUS-Rendezvous or direct intervention
EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
|
Procedure: EUS-Rendezvous or direct intervention |
Active Comparator: Advanced ERCP Biliary Access Techniques
Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
|
Procedure: Advanced ERCP Biliary Access Techniques |
- Biliary access for therapy achieved (wire access across papilla or site of obstruction or wire access to enable successful therapy) [ Time Frame: 24 hours ]Was the endoscopist able to achieve wire access into the biliary system in order to complete the intended therapy? Was intended therapy successful?
- Comparison of adverse events in the two arms. [ Time Frame: Up to 1 month post procedure. ]Was there a difference in adverse events in the two arms. Adverse events include acute pancreatitis, hematoma, bile leak, etc...

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients able to give informed consent
- Patients referred to participating centers for ERCP with the intent to cannulate the bile duct for therapy
Exclusion Criteria:
- Patients with a bleeding diathesis (INR >1.4, platelets <80, current use of anticoagulant medications)
- Patients whose bile ducts are cannulated using standard methods
- Patients with prior biliary sphincterotomy or endoscopic papilla dilation
- Patients with previous surgical biliary-intestinal operations
- Patients with pancreas divisum
- Patients with indwelling pancreatic or biliary stent placement
- Patients who are pregnant or breast-feeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01678326
United States, California | |
California Pacific Medical Center | |
San Francisco, California, United States, 94115 |
Principal Investigator: | Christopher Hamerski, M.D. | California Pacific Medical Center |
Responsible Party: | Christopher Hemerski, Director of Luminal Oncology, California Pacific Medical Center Research Institute |
ClinicalTrials.gov Identifier: | NCT01678326 |
Other Study ID Numbers: |
2012.061-2-JSha |
First Posted: | September 5, 2012 Key Record Dates |
Last Update Posted: | February 7, 2020 |
Last Verified: | February 2020 |
Diseases Classified Elsewhere |
Gallbladder Diseases Biliary Tract Diseases Disease Pathologic Processes Digestive System Diseases |